Surrozen Initiates Dosing in Phase I Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

Surrozen, Inc. announced that the first subject has been dosed in its two-part Phase I clinical trial for SZN-043 which is in development for the potential treatment of severe alcoholic hepatitis.